Monopar Therapeutics Highlights Encouraging Data From Early-Stage Soft Tissue Cancer Study

Monopar Therapeutics Inc MNPR released data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma patients.
The prior exploratory clinical studies of camsirubicin in cancer patients showed the potential to treat patients with high doses for a year or longer.
The preclinical and exploratory clinical studies showed no irreversible heart toxicity with camsirubicin, as seen in doxorubicin, one of the most widely used cancer drugs worldwide.
The Phase 1b clinical trial has enrolled 11 patients. 5 of 10 patients have exhibited stable disease at 12 weeks. 1 patient met the criteria for SD at the first CT scan (6 weeks) but unfortunately died due to COVID-19 and was not evaluable at the 12-week CT scan.
The ASTS subtype patients achieving stable disease on camsirubicin are in line with those more likely to respond to doxorubicin.
The trial is presently at the fourth dose-level cohort (520mg/m2), almost twice the trial's starting dose.
No drug-related clinical cardiotoxicity has been observed in any patient. The trial continues to enroll and dose-escalate, as there have been no signs of hitting the maximum tolerated dose.
Price Action: MNPR shares are up 0.36% at $2.82 on the last check Wednesday.